What is the typical cost of aflibercept injection?
Aflibercept injection, also known as Eylea, is a medication used to treat various eye conditions, including age-related macular degeneration (AMD) and diabetic macular edema (DME). The cost of aflibercept injection can vary depending on several factors, including the location, doctor, and pharmacy.
Average wholesale price (AWP)
According to [1] Drugs.com, the average wholesale price (AWP) for aflibercept injection is around $1,100 to $1,400 per injection, which is administered every 4-6 weeks. However, prices can vary depending on the pharmacy and insurance coverage.
Insurance coverage and patient costs
Insurance coverage plays a significant role in determining the out-of-pocket costs for aflibercept injection. Medicare Part D and private insurance plans may cover some or all of the costs, depending on the specific plan and individual circumstances.
Cost comparison to other treatments
Aflibercept injection is often compared to other treatments for AMD and DME, such as ranibizumab (Lucentis) and bevacizumab (Avastin). According to [2] Retinal Physician, aflibercept injection is often considered a more cost-effective option compared to ranibizumab, particularly for patients with private insurance.
Patent expiration and biosimilar entry
As of 2023, the patent for aflibercept injection is expected to expire in the United States, which may lead to the entry of biosimilars, or cheaper versions of the medication. According to [3] DrugPatentWatch.com, the patent for aflibercept injection is set to expire in 2028, although this date may be subject to change.
Conclusion
The cost of aflibercept injection can vary depending on several factors, including insurance coverage, location, and pharmacy. However, on average, the price ranges from $1,100 to $1,400 per injection. As the patent expires, biosimilars may become available, potentially reducing costs for patients.
Sources
[1] Drugs.com. (n.d.). Aflibercept Injection - Side Effects, Dosage, Price, and Online Pharmacy Information.
[2] Retinal Physician. (2020). Aflibercept vs. Ranibizumab: Cost-effectiveness analysis for treatment of wet AMD.
[3] DrugPatentWatch.com. (n.d.). Eylea (aflibercept injection) Patent Expiration.